BILL ANALYSIS

HR7787

BEARISH

To amend title VII of the Public Health Service Act to strengthen the mental health workforce, and for other purposes.

HR7787 (To amend title VII of the Public Health Service Act to strengthen the mental health workforce, and for other purposes.) has been assessed with a bearish outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bearish

Market Sentiment

2/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

HR7787 is a procedural authorization bill at the earliest committee referral stage with no funding and no Senate companion.

Market impact is negligible; no stock movement can be attributed to this bill based on available data.

Both AMN Healthcare and Centene have seen strong recent gains (+12.6% and +62.55% respectively over 30 days) driven by other market factors, not this legislation.

How HR7787 Affects the Market

No near-term market implications. HR7787 is a procedural health workforce authorization bill with zero appropriations, no legislative momentum, and no identifiable path to enactment in the current session. Investors should monitor committee hearings or a companion Senate bill introduction as triggers for further analysis. Current price action in AMN Healthcare ($20.65, +12.6% monthly) and Centene ($53.22, +62.55% monthly) reflects completely unrelated market dynamics.

Bill Details

Metric	Value
Bill Number	HR7787
Market Sentiment	bearish
Event Date	March 4, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

HR7787 is an early-stage bill authorizing a mental health provider loan forgiveness program. It has been referred to committee with no companion bill, zero appropriations, and minimal legislative momentum. Market impact is negligible at this stage. Real market data shows AMN Healthcare at $20.65, up 12.6% over 30 days, and Centene at $53.22, up 62.55% over 30 days, driven by other factors unrelated to this procedural bill.

Full AI Market Analysis

What happened: HR7787 was introduced on March 4, 2026, by Rep. Troy Carter (D-LA) and referred to the House Committee on Energy and Commerce. It has 4 sponsors (all House members) and no companion Senate bill. The bill authorizes a loan deferment and forgiveness program for mental health providers who work for at least 5 years in designated shortage areas, with forgiveness up to $200,000 in principal and interest. The bill is at the earliest procedural stage. Money trail: This is a pure authorization bill with zero appropriated funding. Section 1 adds a new section to the Public Health Service Act authorizing the Secretary of HHS to establish the program, but no dollar amount is provided for program operations. Any actual spending would require a separate appropriations bill. Authorizations do not guarantee funding; without appropriations, the program cannot exist. Structural winners and losers: At this procedural stage, there are no structural winners or losers. If the bill eventually passed with funding, mental health staffing companies like AMN Healthcare could face reduced temporary staffing demand over the long term, while managed care organizations like Centene could see higher behavioral health utilization. However, the bill is too early-stage and unfunded to drive any near-term market action. Real market data: AMN Healthcare trades at $20.65, 7-day change +1.47%, 30-day change +12.6%. Centene trades at $53.22, 7-day change +27.26%, 30-day change +62.55%. Both stocks have moved significantly over the past month, but these moves are unrelated to HR7787. Centene's sharp 30-day gain is driven by sector-specific or company-specific factors, not this procedural mental health workforce bill. Timeline: The bill must clear the House Energy and Commerce Committee, then pass the full House, then find a Senate companion and pass the Senate, then be signed into law. No hearings, markups, or votes have been scheduled. The 119th Congress runs through 2027, but early-stage health workforce bills without appropriations or broad bipartisan sponsorship face long odds.